After software, it’s pharma ADRs - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

After software, it’s pharma ADRs

Mar 17, 2000

Dr. Reddy’s Laboratories has slated a $ 150 million American Depository Share issue. The report in a financial daily also mentions plans of Ranbaxy and Nicholas Piramal for ADR issues. DRL is one of the fastest growing companies in the pharmaceutical sector having a 1.4% market share in domestic formulations. The company has grown from being a bulk drug company to a respected formulation based company. It has products such as omeprazole (gastro–intestinal), ciprolet (anti–infective) Nise (pain and fever), Enam (cardiovascular) etc.

DRL has three new original molecules in its research pipeline. One is an anti–cancer compound, another was a Cox II inhibitor (anti–pain) and third was a compound indicated for metabolic disorders. The company foresees licensing out two of these to MNCs for clinical trials in the near future.

Its sister concern Cheminor has filed six abbreviated new drug applications (ANDAs) in the US, four in the European Union apart from another six, which are in the pipeline. The company has set a target to file three to five ANDAs every year and have already received approval for ranitidine (75 mg), the anti–ulcerant omeprazole and anti–depressant fluoxetine.

It is quite possible that the company may have plans to integrate Cheminor with itself before it goes in for an ADR listing. This could enable it to get a better price. The management has already announced that Cheminor will be eventually merged with DRL.


Equitymaster requests your view! Post a comment on "After software, it’s pharma ADRs". Click here!

  

More Views on News

BIOCON Share Price Up by 5%; BSE HEALTHCARE Index Up 2.3% (Market Updates)

Sep 25, 2020 | Updated on Sep 25, 2020

BIOCON share price is trading up by 5% and its current market price is Rs 430. The BSE HEALTHCARE is up by 2.3%. The top gainers in the BSE HEALTHCARE Index are BIOCON (up 5.0%) and AUROBINDO PHARMA (up 5.1%). The top losers are SANOFI INDIA (down 0.1%) and ALKEM LABORATORIES (down 1.0%).

ERIS LIFESCIENCES LIMITED Share Price Up by 7%; BSE HEALTHCARE Index Up 2.3% (Market Updates)

Sep 25, 2020 | Updated on Sep 25, 2020

ERIS LIFESCIENCES LIMITED share price is trading up by 7% and its current market price is Rs 560. The BSE HEALTHCARE is up by 2.3%. The top gainers in the BSE HEALTHCARE Index are ERIS LIFESCIENCES LIMITED (up 6.9%) and GLENMARK PHARMA (up 5.2%). The top losers are SANOFI INDIA (down 0.1%) and ALKEM LABORATORIES (down 0.4%).

NATCO PHARMA Share Price Up by 5%; BSE HEALTHCARE Index Up 2.5% (Market Updates)

Sep 25, 2020 | Updated on Sep 25, 2020

NATCO PHARMA share price is trading up by 5% and its current market price is Rs 898. The BSE HEALTHCARE is up by 2.5%. The top gainers in the BSE HEALTHCARE Index is NATCO PHARMA (up 5.4%). The top losers are SANOFI INDIA (down 0.4%) and AJANTA PHARMA (down 0.6%).

CIPLA Share Price Up by 5%; BSE HEALTHCARE Index Up 2.2% (Market Updates)

Sep 25, 2020 | Updated on Sep 25, 2020

CIPLA share price is trading up by 5% and its current market price is Rs 770. The BSE HEALTHCARE is up by 2.2%. The top gainers in the BSE HEALTHCARE Index is CIPLA (up 5.1%). The top losers are SANOFI INDIA (down 0.8%) and AJANTA PHARMA (down 0.8%).

ADVANCED ENZYME TECHNOLOGIES Share Price Up by 10%; BSE HEALTHCARE Index Up 0.4% (Market Updates)

Sep 25, 2020 | Updated on Sep 25, 2020

ADVANCED ENZYME TECHNOLOGIES share price is trading up by 10% and its current market price is Rs 302. The BSE HEALTHCARE is up by 0.4%. The top gainers in the BSE HEALTHCARE Index is ADVANCED ENZYME TECHNOLOGIES (up 10.0%). The top losers are CADILA HEALTHCARE (down 0.1%) and APOLLO HOSPITALS (down 0.2%).

More Views on News

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

How Much Money Do You Need to Be a Professional Trader? (Fast Profits Daily)

Sep 17, 2020

In this video I'll answer a question I get asked often: How much capital do I really need to trade the markets for a living? Let's find out...

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Sep 25, 2020 03:34 PM

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS